Combination for lowering serum phosphate in a patient
TW202045523A
Compounds and methods for treating hyperkalemia
CN111655680A
Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders
WO2019060051A1
Glycyrrhetinic acid derivatives for treating hyperkalemia
WO2018204918A1
Treatment of hepatic disorders
CA3049678A1
Compounds useful for treating gastrointestinal tract disorders
KR20190128626A
Inhibitors of NHE-mediated reverse transport
WO2018129556A1
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US2019233420A1
Hormone receptor modulators for treating metabolic conditions and disorders
US2019308973A1
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
US2017340623A1
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US2017368004A1
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
TW201726597A
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
US2016175345A1
Pharmaceutical compositions for treating hyperkalemia
EP3236940A1
Compositions and methods for treating hyperkalemia
CN105979959A
Compounds and methods for inhibiting phosphate transport
CN105392483A
Nhe3-binding compounds and methods for inhibiting phosphate transport
KR20150073162A
Compounds and methods for inhibiting nhe-mediaded antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
